tiprankstipranks
Verastem (DE:2VS)
FRANKFURT:2VS

Verastem Stock Price & Analysis

0 Followers

2VS Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€0.57
Volume10.00K
Average Volume (3M)4.09K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€94.31M
Total Debt (Recent Filing)€3.07M
P/E RatioN/A
Beta1.38
Next EarningsNov 09, 2022
EPS Estimate-€0.12
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding187,807,568
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume1,673
30 Day Avg. Volume4,088
P/B Ratio1.85
P/S Ratio29.90
P/CF RatioN/A
P/FCF Ratio-2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside974.36% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering3


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

2VS FAQ

What was Verastem’s price range in the past 12 months?
Currently, no data Available
What is Verastem’s market cap?
Currently, no data Available
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Nov 09, 2022 which is in 33 days.
    How were Verastem’s earnings last quarter?
    Verastem released its earnings results on Aug 08, 2022. The company reported -€0.122 earnings per share for the quarter, missing the consensus estimate of -€0.112 by -€0.01.
      Is Verastem overvalued?
      According to Wall Street analysts Verastem’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Verastem pay dividends?
        Verastem does not currently pay dividends.
        What is Verastem’s EPS estimate?
        Verastem’s EPS estimate is -€0.12.
          How many shares outstanding does Verastem have?
          Currently, no data Available
          What happened to Verastem’s price movement after its last earnings report?
          Verastem reported an EPS of -€0.122 in its last earnings report, missing expectations of -€0.112. Following the earnings report the stock price went up 2.4%.
            Which hedge fund is a major shareholder of Verastem?
            Among the largest hedge funds holding Verastem’s share is Graham Capital Management, L.P.. It holds Verastem’s shares valued at N/A.

              ---

              Verastem Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              5
              The Verastem Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Verastem

              Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis